Multiferon (interferon alpha) / SOBI - LARVOL DELTA

YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α (Cancer Immunol Immunother) - Y-box binding protein-1 (YB-1) was poorly expressed in T lymphocytes, as compared with cancer tissues; YB-1 was reported to have an important effect on the STAT3 pathway; Suppression of STAT3 by YB-1 inhibition did not seem to enhance the potential risk for autoimmune disorders

Biomarker • Renal Cell Carcinoma

Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C (Arch Med Res) - PMID: 24051042; P=NA, N=39; "Sustained viral response (SVR) was evaluated according to: a) intention to treat analysis....None of the factors were significantly different in groups a) and b); however, in group c) there was a better response with a marked viral load decline....Five of 39 (13%) patients who completed treatment presented with an SVR. The most common adverse effect was asthenia in 27% of patients."

Clinical data • Hepatitis C Virus

S0412, sorafenib and interferon alfa in treating patients with metastatic or unresectable kidney cancer (clinicaltrials.gov) - P2, N=67; Active, not recruiting -> Completed

Trial completion • Oncology • Renal Cell Carcinoma

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. (PubMed, J Med Case Rep) - P1; "Our patient was treated with repeated intratumoral injections of LTX-315, resulting in tumor regression accompanied by upregulation of immune genes and T-cell infiltration. Local application of immunotherapy, minimizing systemic side effects, represents a novel treatment modality in desmoid tumors that should be tested in further clinical trials."

Clinical • IO Biomarker • Journal